Burnie Academy Academy
When will the new obesity drugs reach India?

When will the new obesity drugs reach India?

The exciting new weight-loss medicines are mostly still in trials. Only one is approved anywhere, and none are sold in India yet. Here is an honest timeline for Indian readers.

13 Jul 2026 · Burnie Academy
obesity-drugs india pipeline cdsco

You heard about amazing new weight-loss shots. Friends talk about retatrutide, cagrisema, orforglipron. The news says people lose 20 to 30 percent of their weight. So when can you get these in India? Let me give you the honest answer. It is not what the WhatsApp forwards say.

What you can actually buy in India today

Here is the real picture right now. The semaglutide patent in India ended on 20 March 2026. The very next day, many Indian companies launched generic semaglutide. Glenmark launched Glipiq, with weekly vial prices starting at Rs 325. Natco launched Semanat and Semafull starting at Rs 1,290 per month in vial form. Six companies launched on Day 1, including Dr Reddy's, Sun Pharma, Glenmark, Alkem, Zydus, and Natco. These are real, legal, CDSCO-approved medicines you can get with a doctor's prescription today. Tirzepatide (Mounjaro) is different. It is still under patent in India, so no legal generic exists yet. So today, your legal choices are: semaglutide generics, or patent-protected tirzepatide at a high price.

The new pipeline drugs — where each one really stands

Here is a simple status table for the seven drugs people ask about most. 'Not in India' means you cannot legally buy it from any Indian pharmacy yet.

Orforglipron (Foundayo, Eli Lilly)
FDA-approved in the US on 1 April 2026 for adults with obesity. It is the first one approved under a new fast-review pilot. But it is NOT approved or sold in India yet.
Retatrutide (Eli Lilly)
Still in Phase 3 trials. People on the 12 mg dose lost 28.3 percent of body weight over 80 weeks. It is an investigational molecule, legally available only to people in Lilly's trials. Not approved anywhere.
CagriSema (Novo Nordisk)
Company filed for FDA approval on 18 December 2025. FDA decision expected around Q4 2026. Not approved yet, anywhere.
MariTide / maridebart cafraglutide (Amgen)
Being studied in the Phase 3 MARITIME trials. It is an investigational medicine. Not approved.
Pemvidutide (Altimmune)
Only Phase 2 data so far. No FDA filing announced. Still investigational. Years from any approval.
Amycretin / zenagamtide (Novo Nordisk)
In early trials — Phase 2 data was published in The Lancet in 2025. Not approved by any regulator anywhere. Earliest approval is years away.
Bimagrumab
Lilly stopped the bimagrumab obesity trial in 2025. Not approved for weight loss anywhere. Development for obesity has been halted.

I saw retatrutide and cagrisema for sale online. I can buy them now.

mostly false

Mostly false — and dangerous. Retatrutide, cagrisema, maritide, pemvidutide, amycretin, and bimagrumab are NOT legally made or approved anywhere in the world yet. So any product sold online with those names is fake or counterfeit. The only exception is orforglipron, approved in the US in April 2026, but it is not legally sold in India. If someone offers you these online in India, it is not the real medicine. Report fake medicines to the drug regulator. Do not inject or swallow something a stranger sold you on the internet.

Once a drug is approved in America, it comes to India in a few weeks.

mostly false

Mostly false — explained simply. Even after a drug wins FDA approval in America, it does NOT come to India automatically. The company must file a fresh application with India's CDSCO. CDSCO checks the trial data and safety before allowing sale. This takes many months to years. Some drugs reach India one to three years after their US launch. Orforglipron was approved in the US in April 2026, but as of today it has no CDSCO approval in India. So do not expect any of the new pipeline drugs in Indian pharmacies for years.

The bottom line

The exciting new obesity drugs are mostly years away from Indian pharmacies. Only orforglipron is approved anywhere (US, April 2026), and it is not in India yet. The rest are still in trials. Today, your real, legal choices are generic semaglutide and patent-protected tirzepatide. Use what is approved, talk to your doctor, and run from anyone selling unapproved 'miracle' drugs online.

Track your food the honest way

Burnie helps you see your estimated calorie deficit with familiar Indian foods — no fake precision, no guilt trips.

Get Burnie on the App Store

Android public availability is being expanded.